ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...
Clinical trial results
Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC
China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...
Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023
China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...
CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment
China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...
Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023
China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...
Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III...
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...
Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Keymed Biosciences’ CM313 Monoclonal Antibody Shows Promise in Phase I Study for Multiple Myeloma
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...
HutchMed Presents Updated Data on Hematological Malignancy Therapies at EHA and ICML
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that new and updated clinical data...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...